Background: The appearance of cerebral venous sinus thrombosis (CVST) in childhood acute lymphocytic leukemia (ALL) is a rare life-threatening disease that can cause significant morbidity, neurological sequelae, and potentially poor outcomes.
Case Presentation: We present the case of a 13-year-old boy with ALL who developed CVST and intrinsic hemorrhage approximately 30 days after receiving chemotherapy with vincristine, dexamethasone, daunorubicin, and pegylated-asparaginase (PEG-Asp). He complained of a severe headache and then developed a generalized seizure at night. T1- and T2-weighted magnetic resonance imaging (MRI) and cerebral magnetic resonance venography sequences revealed superior sagittal sinus thrombosis and intrinsic hemorrhagic changes in the bilateral frontoparietal lobes. He received nadroparin calcium as the anticoagulant treatment and was switched to Erwinia asparaginase (Erwinia Asp) rather than PEG-Asp. Oxcarbazepine and clonazepam were started with good seizure control. Intrathecal treatment was delayed until 1 month later. Anticoagulation treatment was stopped for 24 h before and 6 h after lumbar puncture. Platelet transfusion was administered to ensure the platelet count remained at >50 × 10/L. Oral acetazolamide (500-1,000 mg, daily) was administered to relieve headache and reduce intracranial pressure. Three months later, brain MRI showed a complete resolution of or significant improvement in the filling defect. Nadroparin calcium was administered for 1 week after switching to Erwinia Asp to prevent clot recurrence. He completed the 6-month chemotherapy and is doing well with no neurological sequelae and no recurrence of bleeding or thrombosis.
Conclusions: Nadroparin calcium therapy appears to be safe and effective for pediatric CVST with ALL. The reintroduction of Erwinia Asp should be accompanied by anticoagulant therapy with nadroparin calcium
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11420003 | PMC |
| http://dx.doi.org/10.3389/fped.2024.1448445 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Polycationic γ-Cyclodextrin with Amino Side Chains for a Highly Efficient Anti-Heparin Coagulant.
Adv Healthc Mater
January 2025
College of Chemistry, State Key Laboratory of Elemento-Organic Chemistry, Nankai University, Tianjin, 300071, P. R. China.
Multicharged cyclodextrins have attracted significant attention because of their applications in biology and pharmaceuticals. This study reports an aminoethoxy-phenyl-pyridinium-modified γ-cyclodextrin (PyA-γ-CD) as a highly efficient coagulant for heparin through multivalent interactions. The UV titration experiment is performed to obtain apparent binding constants (K) between PyA-γ-CD and heparin as high as 9.
View Article and Find Full Text PDFA retrospective Cohort study on the effect of the LOw-molecular weighT heparin (LMWH) nadroparin dose on anti-XA levels in a mixed medical-surgical ICU population: CLOT-Xa.
J Crit Care
December 2024
Departments of Intensive Care Medicine, Gelre Hospitals, Albert Schweitzerlaan 31, 7334, DZ, Apeldoorn, the Netherlands; Departments of Expertise Centre for Intensive Care Rehabilitation Apeldoorn - ExpIRA, Gelre Hospitals, Albert Schweitzerlaan 31, 7334, DZ, Apeldoorn, the Netherlands; Department of Intensive Care Medicine, University Medical Center, Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, the Netherlands.
Purpose: Low-molecular-weight heparins (LMWHs) are widely used for prevention and treatment of venous thromboembolism (VTE) in critically ill patients. The objective of this study was to assess the dose-response relationship between nadroparin dose and anti-Xa activity in ICU patients.
Materials And Methods: Critically ill adult patients who were admitted to the ICU, and received at least three subcutaneous injections of nadroparin were included.
Heparin-induced thrombocytopenia during anticoagulation therapy for COVID-19-related pulmonary embolism: A case report.
Medicine (Baltimore)
December 2024
Civil Aviation General Hospital, Beijing, China.
Rationale: One of the main characteristics of COVID-19 is the high incidence of venous thromboembolism, particularly pulmonary embolism. Anticoagulation therapy is the primary treatment for pulmonary embolism. Heparin-induced thrombocytopenia (HIT) is an antibody-mediated adverse reaction to heparin that occurs during its use of heparin drugs.
View Article and Find Full Text PDFBackground: Despite the fact that the COVID-19 epidemic has already ended, there is no clear answer to the question - what is the nature of the imbalance in the hemocoagulation system, and which phenomena prevail - thrombosis or hemorrhage? More and more new works appear describing the occurrence of deep, extensive hematomas in patients with COVID-19. However, this experience requires further discussion and understanding.
Case Description: From October 2020 to January 2021, 7 (2,1% among all hospitalized with COVID-19 in this period) patients with developed hematomas were observed at the COVID-19 hospital.
Cost Analysis of Thromboprophylaxis in Patients at High Thromboembolic Risk with Enoxaparin, Dalteparin and Nadroparin in Colombia: A Systematic Literature Review-Based Study.
Clinicoecon Outcomes Res
November 2024
Department of Health Technology Assessment, ALZAK, Cartagena, Colombia.
Purpose: To analyze the costs of high thromboembolic risk patients who require low molecular weight heparins (LMWHs) as a thromboprophylaxis strategy.
Methods: Cost analysis was conducted to assess LMWHs (enoxaparin versus comparators: nadroparin and dalteparin) as thromboprophylaxis for hospitalized patients with high thromboembolic risk in Oncology, General or Orthopedic Surgery, and Internal Medicine services from the healthcare provider's perspective in Colombia. A decision tree was developed, and the health outcomes considered in the analysis were deep vein thrombosis, major bleeding, pulmonary thromboembolism, and chronic pulmonary hypertension.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!